Endonovo Therapeutics annual operating cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Endonovo Therapeutics Operating Cash Flow Growth & History (ENDV)
Endonovo Therapeutics's operating cash flow was $100,487 for fiscal 2024.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $100,487 | −$21,383 | −17.55% |
| 2023 | 2023-12-31 | $121,870 | $800,708 | — |
| 2022 | 2022-12-31 | −$678,838 | $307,746 | — |
| 2021 | 2021-12-31 | −$986,584 | −$244,994 | — |
| 2020 | 2020-12-31 | −$741,590 | $1.8M | — |
| 2019 | 2019-12-31 | −$2.5M | $337,827 | — |
| 2018 | 2018-12-31 | −$2.9M | $110,936 | — |
| 2017 | 2017-12-31 | −$3.0M | −$527,436 | — |
| 2016 | 2016-12-31 | −$2.5M | −$1.4M | — |
| 2015 | 2015-12-31 | −$1.0M | −$110,038 | — |
| 2014 | 2014-12-31 | −$909,296 | −$651,880 | — |
| 2013 | 2013-12-31 | −$257,416 | $27,475 | — |
| 2012 | 2012-12-31 | −$284,891 | −$234,537 | — |
| 2011 | 2011-12-31 | −$50,354 | −$58,856 | — |
| 2010 | 2010-12-31 | $8,502 | — | — |
Endonovo Therapeutics quarterly operating cash flow
Q1.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q4.15
Q1.16
Q2.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | −$24,836 | — | — |
| Q1 2025 | 2025-03-31 | −$188 | — | — |
| Q4 2024 | 2024-12-31 | $102,763 | — | — |
| Q3 2023 | 2023-09-30 | −$65,367 | $58,494 | — |
| Q2 2023 | 2023-06-30 | −$165,840 | $40,642 | — |
| Q1 2023 | 2023-03-31 | −$173,156 | −$50,202 | — |
| Q4 2022 | 2022-12-31 | −$225,541 | $165,755 | — |
| Q3 2022 | 2022-09-30 | −$123,861 | $45,545 | — |
| Q2 2022 | 2022-06-30 | −$206,482 | −$70,548 | — |
| Q1 2022 | 2022-03-31 | −$122,954 | $166,994 | — |
| Q4 2021 | 2021-12-31 | −$391,296 | −$198,440 | — |
| Q3 2021 | 2021-09-30 | −$169,406 | −$72,733 | — |
| Q2 2021 | 2021-06-30 | −$135,934 | $18,912 | — |
| Q1 2021 | 2021-03-31 | −$289,948 | $7,267 | — |
| Q4 2020 | 2020-12-31 | −$192,856 | $115,525 | — |
| Q3 2020 | 2020-09-30 | −$96,673 | $920,097 | — |
| Q2 2020 | 2020-06-30 | −$154,846 | $532,777 | — |
| Q1 2020 | 2020-03-31 | −$297,215 | $231,018 | — |
| Q4 2019 | 2019-12-31 | −$308,381 | $407,714 | — |
| Q3 2019 | 2019-09-30 | −$1.0M | −$186,392 | — |
| Q2 2019 | 2019-06-30 | −$687,623 | $53,987 | — |
| Q1 2019 | 2019-03-31 | −$528,233 | $62,518 | — |
| Q4 2018 | 2018-12-31 | −$716,095 | $84,479 | — |
| Q3 2018 | 2018-09-30 | −$830,378 | $10,979 | — |
| Q2 2018 | 2018-06-30 | −$741,610 | $172,037 | — |
| Q1 2018 | 2018-03-31 | −$590,751 | −$156,559 | — |
| Q4 2017 | 2017-12-31 | −$800,574 | −$141,924 | — |
| Q3 2017 | 2017-09-30 | −$841,357 | −$65,715 | — |
| Q2 2017 | 2017-06-30 | −$913,647 | −$310,474 | — |
| Q1 2017 | 2017-03-31 | −$434,192 | −$9,323 | — |
| Q4 2016 | 2016-12-31 | −$658,650 | −$447,361 | — |
| Q2 2016 | 2016-09-30 | −$775,642 | −$346,419 | — |
| Q1 2016 | 2016-06-30 | −$603,173 | −$418,187 | — |
| Q4 2015 | 2016-03-31 | −$424,869 | −$231,033 | — |
| Q4 2015 | 2015-12-31 | −$211,289 | $16,445 | — |
| Q3 2015 | 2015-09-30 | −$429,223 | −$233,120 | — |
| Q2 2015 | 2015-06-30 | −$184,986 | $104,543 | — |
| Q1 2015 | 2015-03-31 | −$193,836 | $2,094 | — |
| Q4 2014 | 2014-12-31 | −$227,734 | −$174,069 | — |
| Q3 2014 | 2014-09-30 | −$196,103 | −$167,941 | — |
| Q2 2014 | 2014-06-30 | −$289,529 | −$230,171 | — |
| Q1 2014 | 2014-03-31 | −$195,930 | −$79,699 | — |
| Q4 2013 | 2013-12-31 | −$53,665 | $2,029 | — |
| Q3 2013 | 2013-09-30 | −$28,162 | $4,877 | — |
| Q2 2013 | 2013-06-30 | −$59,358 | $116,482 | — |
| Q1 2013 | 2013-03-31 | −$116,231 | −$95,913 | — |
| Q4 2012 | 2012-12-31 | −$55,694 | — | — |
| Q3 2012 | 2012-09-30 | −$33,039 | — | — |
| Q2 2012 | 2012-06-30 | −$175,840 | — | — |
| Q1 2012 | 2012-03-31 | −$20,318 | −$20,318 | — |
| Q1 2011 | 2011-03-31 | $0 | — | — |
Endonovo Therapeutics operating cash flow trends
Over the last five fiscal years, Endonovo Therapeutics's operating cash flow increased from −$2.5M to $100,487, a change of $2.6M. The latest reported quarter, Q2 2025, shows −$24,836.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗